Suppr超能文献

炎症性肠病中的药物性痤疮:胃肠病学家实用指南

Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist.

作者信息

Temido Maria José, Honap Sailish, Bursztejn Anne Claire, Portela Francisco, Jairath Vipul, Danese Silvio, Spencer Ashley, Peyrin-Biroulet Laurent

机构信息

INFINY Institute, Department of Gastroenterology, Nancy University Hospital, Nancy, France.

Gastroenterology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.

出版信息

Am J Gastroenterol. 2025 Jan 1;120(1):125-134. doi: 10.14309/ajg.0000000000003119. Epub 2024 Oct 9.

Abstract

Drug-induced acne is a common side effect to a wide array of pharmacological therapies and is characterized by a monomorphic, papulopustular eruption typically affecting the face, scalp, and the upper thorax. Corticosteroids and Janus kinase inhibitors (JAKi) are commonly used for the treatment of inflammatory bowel disease (IBD) and are known to aggravate a prior tendency to acne or trigger the development of new acneiform eruptions. Recent attention on managing drug-induced acne has been driven by the increasing use of JAKi, an expanding therapeutic class in IBD and several other immune-mediated inflammatory diseases. Both randomized controlled trials and real-world studies have identified acne as one of the most common treatment-emergent adverse events in JAKi. Left untreated, this common skin reaction can significantly affect patient self-esteem and quality of life leading to poor treatment adherence and suboptimal IBD control. This review examines the characteristics of drug-induced acne in IBD treatments, provides a practical guide for gastroenterologists to manage mild-to-moderate occurrences, and highlights when to seek specialist dermatology advice. Such approaches enable early treatment of a common and often distressing adverse event and optimize the management of IBD by preventing the premature discontinuation or dose reduction of efficacious IBD drugs.

摘要

药物性痤疮是多种药物治疗常见的副作用,其特征为单一形态的丘疹脓疱性皮疹,通常累及面部、头皮和上胸部。皮质类固醇和 Janus 激酶抑制剂(JAKi)常用于治疗炎症性肠病(IBD),已知会加重既往的痤疮倾向或引发新的痤疮样皮疹。对药物性痤疮管理的近期关注是由 JAKi 使用的增加所推动的,JAKi 在 IBD 和其他几种免疫介导的炎症性疾病中是一个不断扩大的治疗类别。随机对照试验和真实世界研究均已将痤疮确定为 JAKi 治疗中最常见的治疗中出现的不良事件之一。若不治疗,这种常见的皮肤反应会显著影响患者的自尊和生活质量,导致治疗依从性差以及 IBD 控制不佳。本综述探讨了 IBD 治疗中药物性痤疮的特征,为胃肠病学家管理轻度至中度病例提供实用指南,并强调何时寻求皮肤科专科建议。此类方法能够对这一常见且往往令人苦恼的不良事件进行早期治疗,并通过防止有效 IBD 药物过早停药或减量来优化 IBD 的管理。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验